Image_01
© David Ausserhofer

Technology Transfer

The Technology Transfer Office works with the research community at the MDC to translate their ideas and discoveries into products and services for public benefit. We support applied research, safeguard IP and connect our researchers with external experts and industry to turn research and ideas into technology opportunities and new businesses.

Related news & events

neoplastische Plasmazellen exprimieren MAGE-A1

In multiple myeloma, the bone marrow contains many degenerate plasma cells that produce the antigen MAGE-1A (brown). The T cells, genetically engineered with a MAGE-1A-specific receptor, recognize the antigen and target the tumor cells. 

© von Brünneck / Charité
Press Release No. 15

New cancer-fighting immunotherapy enters clinical trials

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells. The safety of the novel therapy is now being tested on patients with bone marrow cancer in a phase I clinical trial.
Teaserbild Ingo Curdt
© Felix Petermann, MDC
Institute & Campus

SPOT: Giving start-ups a head start

With its spin-off support program SPOT, the MDC is giving a helping hand to teams looking to start a company. Three of the most promising projects have now been selected. For our series “We at the MDC” we spoke with Dr. Ingo Curdt, coordinator of the funding program.
Dr. Kyle Ira Harrington

Dr. Kyle Ira Harrington

© Felix Petermann, MDC
Science

The big picture

Kyle Harrington will lead a new MDC technology platform developing new tools to process any type of imaging data. The new unit will support the Helmholtz Imaging Platform (HIP), a joint effort by the MDC and two other centers to advance image data acquisition, preparation and analysis.
Cells leaving Primary Tumor

Cells leaving Primary Tumor. The gene bambi changes tumor cells in such a way that single cells break off from the primary tumor and spread to other body regions to form metastases. Changed tumor cells, that have left the primary tumor. (in red: cytoskeleton; in blue: the cell nucleus).

© Johannes Fritzmann, MDC
Press Release No. 34

€66 million for the Berlin spin-off T-knife

The Berlin biotech start-up T-knife, a spin-off from the MDC together with Charité, has secured investments totaling €66 million. Four venture capital funds committed to the financing in early August. T-knife develops new cancer treatments using modified immune system T cells.